Pfizer Inc. (NYSE:PFE) Holdings Raised by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. grew its position in Pfizer Inc. (NYSE:PFE) by 43.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 78,734 shares of the biopharmaceutical company’s stock after acquiring an additional 23,783 shares during the quarter. Pfizer makes up approximately 0.8% of Roman Butler Fullerton & Co.’s holdings, making the stock its 29th largest position. Roman Butler Fullerton & Co.’s holdings in Pfizer were worth $2,163,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in PFE. Moneta Group Investment Advisors LLC grew its stake in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank acquired a new position in Pfizer during the 4th quarter worth $3,150,472,000. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley boosted its position in Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in Pfizer during the 1st quarter worth $311,238,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 0.3 %

NYSE:PFE traded down $0.07 during trading hours on Thursday, hitting $25.35. 4,979,347 shares of the company’s stock traded hands, compared to its average volume of 42,050,078. The firm has a market cap of $143.55 billion, a P/E ratio of 70.57, a P/E/G ratio of 1.16 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.26 and a twelve month high of $40.56. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock’s fifty day moving average price is $27.19 and its two-hundred day moving average price is $28.76.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.